FDA panel considers a first-of-its-kind flu vaccine using mRNA technology

The FDA advisory panel is evaluating Moderna's first mRNA-based flu vaccine, mFlusiva, for approval in adults 50 and older. The vaccine, which showed a 27% reduction in flu cases compared to a standard-dose vaccine in a 40,000-person study, faces scrutiny over its study design but has received a favorable FDA review with no safety concerns noted.